Today: 11 februari 2026
Subscribe
Search result

Phantom 4 RTK/feed/category/dji-mavic-3t-pl- Page 272

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics shares jumped nearly 50% to $1.80 intraday on October 29, 2025, after announcing a manufacturing partnership with Cellipont Bioservices to advance its ovarian cancer cell therapy, ERNA-101, toward clinical trials. Trading volume surged. Despite the rally, ERNA stock remains down about 58% in 2025 and 89% year-on-year after previous setbacks and a reverse stock split.
29 oktober 2025
·
Chipotle Stock Tumbles on Third Forecast Cut — Can the Burrito Chain Bounce Back?

Chipotle Stock Craters After Tepid Q3 Earnings – What’s Next for CMG?

Chipotle shares plunged 18% pre-market Oct. 30 after management cut its 2025 same-store sales forecast to a low-single-digit decline, citing persistent macroeconomic pressures. Q3 revenue rose 7.5% to $3.0 billion, but same-store sales grew just 0.3% as customer traffic fell for the third straight quarter. Chipotle opened 84 new restaurants and repurchased $686.5 million in stock. The stock is down 34% year-to-date.
30 oktober 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.
30 oktober 2025
··
QuantumScape (QS) Stock Soars 200% on EV Battery Breakthroughs – What’s Next for This High-Voltage Bet?

QuantumScape (QS) Stock Soars 200% on EV Battery Breakthroughs – What’s Next for This High-Voltage Bet?

QuantumScape shares have surged about 180% in 2025, hitting nearly $19 before settling near $17 in late October. Q3 results showed a net loss of $0.18 per share, no product revenue, but $12.8 million in customer billings and $1 billion in liquidity. Major partnerships were signed with Corning and Murata, and Volkswagen advanced $260 million in royalties. Most analysts remain cautious, with consensus targets well below current prices.
31 oktober 2025
Astera Labs Stock Skyrockets on AI Buzz and Photonics Deal – Can ALAB Keep Climbing?

Astera Labs Stock Skyrockets on AI Buzz and Photonics Deal – Can ALAB Keep Climbing?

Astera Labs shares surged over 12% to $191 intraday on Oct. 31, 2025, though still below their September high of $262.90. The stock rebounded after a volatile month that included a 19% drop on Oct. 15 and the Oct. 22 acquisition of aiXscale Photonics. Q2 revenue jumped 150% year-over-year to $191.9 million, beating estimates. Institutional investors hold about 60% of shares, while insiders sold over $190 million in August.
31 oktober 2025
··
Adtalem (ATGE) Stock Plummets 27% After Earnings – Latest News, Key Facts & Expert Outlook

Adtalem (ATGE) Stock Plummets 27% After Earnings – Latest News, Key Facts & Expert Outlook

Adtalem Global Education posted Q1 adjusted EPS of $1.75, up 35.7% year-over-year, on $462.3 million revenue, beating estimates. Shares plunged 27% to $102 after the report, despite reaffirmed guidance and strong results. Insider selling, including a director’s 25,500-share sale, weighed on sentiment. Market cap now stands near $3.7 billion; analysts remain mostly bullish with a $146 average target.
31 oktober 2025
··
Virgin Galactic’s Wild 2025 Ride: Space Tourism Liftoff, Stock Surges & Cash Burn – What’s Next for SPCE?

Virgin Galactic’s Wild 2025 Ride: Space Tourism Liftoff, Stock Surges & Cash Burn – What’s Next for SPCE?

Virgin Galactic shares surged over 40% in October 2025 before dropping back, closing at $3.94 on Oct. 31, down about 40% year-to-date and 99% below their 2021 peak. The company paused commercial flights after June 2024 and is burning $100–125 million per quarter, with about 18 months of cash left. Wall Street targets hover near $4, with some analysts warning of further downside.
1 november 2025
··
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 november 2025
AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital (HKD) Skyrockets 180% on 1,085% Revenue Surge – Meme-Stock Mania 2.0 or Sustainable Comeback?

AMTD Digital shares surged 224% to a $5.47 intraday high on Oct. 31, 2025, before closing up 75% at $2.95, with trading volume topping 323 million shares. The company reported a 1,085.9% year-over-year revenue jump to $73.2 million for the half-year ended April 2025, driven by its TGE acquisition. Net profit hit $51.5 million, but most gains came from one-off investment income. HKD now trades near $3.00.
3 november 2025
IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀

IDEXX Laboratories reported Q3 2025 revenue of $1.11 billion, up 13%, and EPS of $3.40, up 21%, beating expectations and raising full-year guidance. Shares have surged about 50–55% year-to-date, trading near all-time highs. The company holds nearly half the global veterinary diagnostics market and generates about 79% of sales from recurring revenue. Institutional ownership stands at approximately 94%.
3 november 2025
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 november 2025
·
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Technologies shares surged 1,300% from June lows, averting Nasdaq delisting and prompting the company to cancel a planned reverse split. Despite the rally, Opendoor posted a $29 million Q2 loss and expects Q3 revenue to fall sharply. The company named Kaz Nejatian CEO in September, shifting focus to AI-powered real estate. Wall Street analysts remain skeptical, with price targets below current levels.
3 november 2025
·
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB named Chirantan “CJ” Desai as its next CEO, replacing Dev Ittycheria, who will step down in November 2025 after 11 years. Shares jumped about 9% in pre-market trading, nearing all-time highs, as the company raised its Q3 FY2026 outlook and analysts boosted price targets. Ittycheria will stay on as an advisor during the transition. Final Q3 results are due December 1, 2025.
3 november 2025
··
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 november 2025
···
1 … 270 271 272 273 274 … 278
Go toTop